Erlotinib, a first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drug, blocks the activity of EGFR tyrosine kinase, thus inhibiting the activation of downstream pathways and reducing angiogenesis and the proliferation, differentiation, and metastasis of tumor cells. The gene discussed is EGFR; the disease is neoplasm.